Incyte (INCY) Q2 Revenue Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Incyte Reports 2018 Second Quarter Financial Results and Updates on Key Clinical Programs
July 31, 2018 7:00 AM EDTTotal product-related revenues of $421 million in Q2 2018, representing 29 percent growth over the same period last year; Jakafi® (ruxolitinib) revenues of $346 million in Q2 2018, representing 25 percent growth over the same period last year Pivotal REACH1 study of Jakafi in steroid-refractory acute GVHD met primary endpoint; sNDA submission expected in Q3 2018 Later-stage portfolio provides potential for accelerated growth from multiple near-to-market opportunities
Second Quarter Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte... More
